SCYNEXIS

$8.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) As of 2:37 PM UTC today

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, and ETFs commission-free!

About SCYX

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ. The listed name for SCYX is SCYNEXIS, Inc. Common Stock.

CEO
Marco Taglietti
Employees
27
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
87.68M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.22M
High Today
$8.13
Low Today
$7.85
Open Price
$8.05
Volume
206.62K
52 Week High
$11.90
52 Week Low
$4.20

Collections

SCYX Earnings

-$1.19
-$0.79
-$0.40
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

HTBI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure